Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4e245372d40118e1d2d7c3ccc2d9822a http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e67b3d73a862737a4c8aae73cb411ec3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fe83b44c8ddc16aff9457df85f4ba8a0 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-025 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-19 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
filingDate |
2012-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a182d4f3807f7d5849205adf23d87e13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd355d6fe58a29c55229593ee6d687b8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f89ec1b96893721aab8f20b2fd1084c8 |
publicationDate |
2012-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2012263684-A1 |
titleOfInvention |
Novel methods for modulating inflammatory and/or immune responses |
abstract |
The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents. |
priorityDate |
2007-01-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |